title: A combination of receptor-based pharmacophore modeling & QM techniques for identification of human chymase inhibitors.
abstract: Inhibition of chymase is likely to divulge therapeutic ways for the treatment of cardiovascular diseases, and fibrotic disorders. To find novel and potent chymase inhibitors and to provide a new idea for drug design, we used both ligand-based and structure-based methods to perform the virtual screening(VS) of commercially available databases. Different pharmacophore models generated from various crystal structures of enzyme may depict diverse inhibitor binding modes. Therefore, multiple pharmacophore-based approach is applied in this study. X-ray crystallographic data of chymase in complex with different inhibitors were used to generate four structure-based pharmacophore models. One ligand-based pharmacophore model was also developed from experimentally known inhibitors. After successful validation, all pharmacophore models were employed in database screening to retrieve hits with novel chemical scaffolds. Drug-like hit compounds were subjected to molecular docking using GOLD and AutoDock. Finally four structurally diverse compounds with high GOLD score and binding affinity for several crystal structures of chymase were selected as final hits. Identification of final hits by three different pharmacophore models necessitates the use of multiple pharmacophore-based approach in VS process. Quantum mechanical calculation is also conducted for analysis of electrostatic characteristics of compounds which illustrates their significant role in driving the inhibitor to adopt a suitable bioactive conformation oriented in the active site of enzyme. In general, this study is used as example to illustrate how multiple pharmacophore approach can be useful in identifying structurally diverse hits which may bind to all possible bioactive conformations available in the active site of enzyme. The strategy used in the current study could be appropriate to design drugs for other enzymes as well.
authors: Division of Applied Life Science (BK21 Program), Systems and Synthetic Agrobiotech Center (SSAC), Plant Molecular Biology and Biotechnology Research Center (PMBBRC), Research Institute of Natural Science (RINS), Gyeongsang National University (GNU), Jinju, Republic of Korea.
authors: Mahreen
authors: M
authors: Arooj
authors: Sugunadevi
authors: S
authors: Sakkiah
authors: Songmi
authors: S
authors: Kim
authors: Venkatesh
authors: V
authors: Arulalapperumal
authors: Keun Woo
authors: KW
authors: Lee
mesh_terms: D002316:Cardiotonic Agents / Q000737:chemistry*; D020134:Catalytic Domain; D053818:Chymases / Q000037:antagonists & inhibitors* / Q000737:chemistry; D018360:Crystallography, X-Ray; D062126:Databases, Chemical; D015195:Drug Design; D006801:Humans; D008024:Ligands; D062105:Molecular Docking Simulation; D011480:Protease Inhibitors / Q000737:chemistry*; D011485:Protein Binding; D011789:Quantum Theory; D013329:Structure-Activity Relationship
chemical_list: D002316:Cardiotonic Agents; D008024:Ligands; D011480:Protease Inhibitors; D053818:Chymases
references: J Chem Inf Model. 2009 Jun;49(6):1581-9
references: 19449853
references: Eur Heart J. 2010 Mar;31(6):642-8
references: 20176800
references: J Med Chem. 2007 Apr 19;50(8):1727-30
references: 17361995
references: Phys Rev B Condens Matter. 1988 Jan 15;37(2):785-789
references: 9944570
references: RNA. 2008 Aug;14(8):1501-7
references: 18566190
references: Bioorg Med Chem Lett. 1999 Feb 8;9(3):413-8
references: 10091694
references: J Chem Inf Model. 2010 Aug 23;50(8):1432-41
references: 20726600
references: J Am Soc Nephrol. 2003 Jul;14(7):1738-47
references: 12819233
references: Biochem Pharmacol. 2010 Oct 1;80(7):1033-41
references: 20599788
references: J Phys Chem A. 2010 Dec 30;114(51):13381-7
references: 21126064
references: J Chem Inf Model. 2009 Feb;49(2):492-502
references: 19434847
references: J Med Chem. 1997 Jul 4;40(14):2156-63
references: 9216834
references: ACS Med Chem Lett. 2011 Apr 12;2(7):489-93
references: 24900336
references: J Mol Graph Model. 2013 May;42:17-25
references: 23507201
references: Bioorg Med Chem Lett. 2001 Jul 9;11(13):1691-4
references: 11425539
references: J Comput Aided Mol Des. 2007 Jun;21(6):311-25
references: 17294248
references: J Biol Chem. 2005 May 6;280(18):18001-7
references: 15741158
references: Biochim Biophys Acta. 2000 Jul 14;1480(1-2):245-57
references: 10899625
references: J Chem Inf Model. 2009 May;49(5):1234-44
references: 19382744
references: Int J Mol Sci. 2011;12(12):9236-64
references: 22272131
references: PLoS One. 2011;6(11):e27990
references: 22132188
references: Bioorg Med Chem Lett. 2011 Aug 1;21(15):4533-9
references: 21733690
references: Nat Rev Drug Discov. 2004 May;3(5):417-29
references: 15136789
references: Bioorg Med Chem Lett. 2000 Nov 6;10(21):2397-401
references: 11078187
references: Med Chem. 2007 Mar;3(2):187-97
references: 17348856
references: Bioorg Med Chem. 2011 Dec 1;19(23):7168-80
references: 22018919
references: Genet Med. 2008 Aug;10(8):593-8
references: 18641516
references: Am J Hypertens. 1996 Mar;9(3):277-84
references: 8695029
references: Bioorg Med Chem. 2001 Nov;9(11):3065-75
references: 11597491
references: J Chem Inf Model. 2011 Sep 26;51(9):2147-55
references: 21434646
references: Pharmacol Rev. 2000 Mar;52(1):11-34
references: 10699153
references: J Antimicrob Chemother. 2004 Jan;53(1):65-73
references: 14645324
references: J Am Chem Soc. 2008 Sep 24;130(38):12725-33
references: 18729359
references: J Immunol. 2006 Dec 15;177(12):8315-9
references: 17142727
references: Curr Opin Drug Discov Devel. 2003 May;6(3):370-6
references: 12833670
references: J Chem Inf Model. 2009 Jun;49(6):1497-513
references: 19453153
references: Bioorg Med Chem Lett. 2003 Jan 6;13(1):25-9
references: 12467610